AndrewChristopherJohnsMD

Ohio state

Dr. Johns is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

I am a clinical fellow in hematology and medical oncology at MD Anderson Cancer Center.

PubMed

Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma.
Mohammad Jad Moussa, Jaanki Khandelwal, Nathaniel R Wilson, Kiran L Malikayil, Devaki Shilpa Surasi
Journal for Immunotherapy of Cancer. 2025-02-12
Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma.
Emily Wang, Eric S Rupe, Sagar S Mukhida, Andrew C Johns, Matthew T Campbell
European Urology Focus. 2024-09-21
3 citations
Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma.
Andrew C Johns, Matthew T Campbell, Mamie Gao, Andrew W Hahn, Zita Lim
The Oncologist. 2024-07-05

Journal Articles

"Linguistic politeness and pragmatic variation in request production in Dakar French"
Johns, Andrew, and J. César Félix-Brasdefer, Journal of Politeness Research, 2/1/2015

Lectures

Is immunotherapy toxicity associated with improved overall survival among older adults with advanced cancer?
2019 ASCO Annual Meeting - 6/1/2019
Total Hip Arthroplasty: A Retrospective Review of the Anterior Approach
Fort Wayne, Indiana - 8/6/2014